Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 3/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014751 | 0.89 | LMNA (0.41) | ALOX15HTTTNFAOC3KMT2A | |
| SCHEMBL2008589 | 0.88 | ITGB3 (0.44) | TNFMAPK14MEN1KMT2AHTR1D | |
| SCHEMBL2008555 | 0.81 | LMNA (0.39) | TNFAOC3MEN1KMT2ATSHR | |
| SCHEMBL7126904 | 0.76 | ALOX15 (0.52) | ALOX15HTTTNFAOC3PIN1 | |
| SCHEMBL2008883 | 0.73 | ALOX15 (0.49) | ALOX15HTTAOC3PIN1PIN4 | |
| SCHEMBL31576686 | 0.73 | ALOX15 (0.47) | ALOX15HTTAOC3PIN1PIN4 | |
| SCHEMBL2011706 | 0.72 | ALOX15 (0.47) | ALOX15HTTTNFAOC3PIN1 | |
| SCHEMBL13332234 | 0.72 | BRD4 (0.46) | HTTMEN1KMT2APLK1TSHR | |
| SCHEMBL13332215 | 0.72 | S1PR1 (0.47) | HTTPLK1TSHRNFKB1RAB9A | |
| SCHEMBL1500291 | 0.71 | GRM1 (0.54) | ALOX15AOC3L3MBTL1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | ALOX15 2131/4885HTT 1966/4885TNF 1537/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | ALOX15 2131/4885HTT 1966/4885TNF 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.